CN103242227A - 一种托拉塞米化合物及其药物组合物 - Google Patents
一种托拉塞米化合物及其药物组合物 Download PDFInfo
- Publication number
- CN103242227A CN103242227A CN2013101462107A CN201310146210A CN103242227A CN 103242227 A CN103242227 A CN 103242227A CN 2013101462107 A CN2013101462107 A CN 2013101462107A CN 201310146210 A CN201310146210 A CN 201310146210A CN 103242227 A CN103242227 A CN 103242227A
- Authority
- CN
- China
- Prior art keywords
- torasemide
- compound
- pharmaceutical composition
- solution
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005461 torasemide Drugs 0.000 title claims abstract description 139
- -1 Torasemide compound Chemical class 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims abstract description 101
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 42
- 239000013078 crystal Substances 0.000 claims abstract description 35
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 16
- 229930195725 Mannitol Natural products 0.000 claims abstract description 16
- 239000000594 mannitol Substances 0.000 claims abstract description 16
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 9
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 8
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 8
- 230000005260 alpha ray Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 60
- 239000000243 solution Substances 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 29
- 239000007924 injection Substances 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000012046 mixed solvent Substances 0.000 claims description 19
- 235000017550 sodium carbonate Nutrition 0.000 claims description 19
- 238000004108 freeze drying Methods 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- 238000012856 packing Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003637 basic solution Substances 0.000 claims description 7
- 239000012043 crude product Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 229940125773 compound 10 Drugs 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 238000005261 decarburization Methods 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 101100002917 Caenorhabditis elegans ash-2 gene Proteins 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000013112 stability test Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 11
- 238000005070 sampling Methods 0.000 description 11
- 238000007789 sealing Methods 0.000 description 11
- 238000004088 simulation Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 230000001882 diuretic effect Effects 0.000 description 8
- 229960003883 furosemide Drugs 0.000 description 7
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 7
- 229940097420 Diuretic Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000002934 diuretic Substances 0.000 description 6
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000013618 particulate matter Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DGIINIBYHCODIH-UHFFFAOYSA-N 4-chloropyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC=C1Cl DGIINIBYHCODIH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
实施例1 | 对比例1 | 对比例2 | 对比例3 | 对比例4 | |
无水乙醚与乙酸乙酯的体积比 | 5:1 | 2:1 | 1:1 | 1:2 | 1:3 |
收率 | 96.5% | 96.6% | 96.2% | 83.2% | 80.2% |
活性炭浓度(w/v)% | 产率(%) | 纯度(%) |
0.5 | 93.8 | 99.89 |
0.2 | 95.1 | 99.94 |
0.1 | 98.7 | 99.99 |
0.05 | 98.8 | 99.93 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310146210.7A CN103242227B (zh) | 2013-04-24 | 2013-04-24 | 一种托拉塞米化合物及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310146210.7A CN103242227B (zh) | 2013-04-24 | 2013-04-24 | 一种托拉塞米化合物及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242227A true CN103242227A (zh) | 2013-08-14 |
CN103242227B CN103242227B (zh) | 2015-05-13 |
Family
ID=48922133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310146210.7A Expired - Fee Related CN103242227B (zh) | 2013-04-24 | 2013-04-24 | 一种托拉塞米化合物及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103242227B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997860A (zh) * | 2016-07-09 | 2016-10-12 | 南京臣功制药股份有限公司 | 一种托拉塞米注射液及其制备方法 |
CN109200022A (zh) * | 2017-06-29 | 2019-01-15 | 南京优科生物医药研究有限公司 | 一种注射用托拉塞米及其制备工艺 |
CN111568868A (zh) * | 2020-06-24 | 2020-08-25 | 福州华为医药技术开发有限公司 | 注射用托拉塞米的制备方法 |
CN112168776A (zh) * | 2020-10-30 | 2021-01-05 | 康普药业股份有限公司 | 一种低杂质高稳定的托拉塞米注射液和制备方法 |
CN113514584A (zh) * | 2021-07-13 | 2021-10-19 | 辽宁省药品检验检测院 | 一种对食品中非法添加的托拉塞米进行定性、定量检测的方法及应用 |
CN114376969A (zh) * | 2020-10-19 | 2022-04-22 | 南京济群医药科技股份有限公司 | 一种托拉塞米注射液及其制备方法 |
CN117510444A (zh) * | 2024-01-06 | 2024-02-06 | 成都瑞尔医药科技有限公司 | 一种呋塞米的精制工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1833642A (zh) * | 2006-04-20 | 2006-09-20 | 南京海辰药业有限公司 | 托拉塞米冻干制剂及制备方法 |
CN101717365A (zh) * | 2009-10-09 | 2010-06-02 | 天茂实业集团股份有限公司 | 托拉塞米的纯化及制备大晶型方法 |
-
2013
- 2013-04-24 CN CN201310146210.7A patent/CN103242227B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1833642A (zh) * | 2006-04-20 | 2006-09-20 | 南京海辰药业有限公司 | 托拉塞米冻干制剂及制备方法 |
CN101717365A (zh) * | 2009-10-09 | 2010-06-02 | 天茂实业集团股份有限公司 | 托拉塞米的纯化及制备大晶型方法 |
Non-Patent Citations (1)
Title |
---|
JUDITH MARIA ROLLINGER: "Crystal forms of torasemide: new insights", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》, 31 December 2002 (2002-12-31), pages 75 - 86 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997860A (zh) * | 2016-07-09 | 2016-10-12 | 南京臣功制药股份有限公司 | 一种托拉塞米注射液及其制备方法 |
CN105997860B (zh) * | 2016-07-09 | 2021-03-09 | 南京臣功制药股份有限公司 | 一种托拉塞米注射液及其制备方法 |
CN109200022A (zh) * | 2017-06-29 | 2019-01-15 | 南京优科生物医药研究有限公司 | 一种注射用托拉塞米及其制备工艺 |
CN109200022B (zh) * | 2017-06-29 | 2021-09-10 | 南京优科生物医药研究有限公司 | 一种注射用托拉塞米及其制备工艺 |
CN111568868A (zh) * | 2020-06-24 | 2020-08-25 | 福州华为医药技术开发有限公司 | 注射用托拉塞米的制备方法 |
CN111568868B (zh) * | 2020-06-24 | 2022-04-19 | 福州华为医药技术开发有限公司 | 注射用托拉塞米的制备方法 |
CN114376969A (zh) * | 2020-10-19 | 2022-04-22 | 南京济群医药科技股份有限公司 | 一种托拉塞米注射液及其制备方法 |
CN112168776A (zh) * | 2020-10-30 | 2021-01-05 | 康普药业股份有限公司 | 一种低杂质高稳定的托拉塞米注射液和制备方法 |
CN112168776B (zh) * | 2020-10-30 | 2022-05-03 | 康普药业股份有限公司 | 一种低杂质高稳定的托拉塞米注射液和制备方法 |
CN113514584A (zh) * | 2021-07-13 | 2021-10-19 | 辽宁省药品检验检测院 | 一种对食品中非法添加的托拉塞米进行定性、定量检测的方法及应用 |
CN117510444A (zh) * | 2024-01-06 | 2024-02-06 | 成都瑞尔医药科技有限公司 | 一种呋塞米的精制工艺 |
CN117510444B (zh) * | 2024-01-06 | 2024-03-08 | 成都瑞尔医药科技有限公司 | 一种呋塞米的精制工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN103242227B (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103242227B (zh) | 一种托拉塞米化合物及其药物组合物 | |
CN102964257B (zh) | 一种盐酸氨溴索化合物及其药物组合物 | |
CN102512380B (zh) | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 | |
WO2021227146A1 (zh) | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 | |
CN105036881A (zh) | 一种改善土壤环境的含有茶叶渣的花生肥料添加剂 | |
CN102643255B (zh) | 一种炎琥宁化合物 | |
CN102321007B (zh) | 一种奥拉西坦化合物、制备方法及其药物组合物 | |
CN103896930A (zh) | 卡格列净半水合物药用晶型的制备方法 | |
CN101756914A (zh) | 一种奥美拉唑钠的冻干粉针剂及其制备方法 | |
CN102358721B (zh) | 一种更为稳定的乙酰谷酰胺化合物及其药物组合物 | |
CN103145735B (zh) | 一种注射用盐酸头孢甲肟化合物及其药物组合物 | |
CN105232503B (zh) | 一种盐酸达泊西汀片 | |
CN105669543A (zh) | 异甘草素烟酰胺共晶及其制备方法 | |
CN103923117B (zh) | 一种有生物活性的希夫碱氧钒配合物晶体的制备方法 | |
CN103232443B (zh) | 一种吲唑衍生物的晶型及其制备和用途 | |
CN102584862B (zh) | 一种比阿培南结晶化合物及其组合物粉针 | |
CN105646520A (zh) | 一种稳定的艾日布林化合物 | |
CN104130110A (zh) | 白藜芦醇的提取方法及其获得的白藜芦醇和药物组合物 | |
CN110548005A (zh) | 含有多奈哌齐衍生物的缓释注射制剂 | |
CN107629055A (zh) | 一种氨苯蝶啶化合物及其制备方法 | |
CN105125498A (zh) | 一种降血脂药物匹伐他汀钙组合物干混悬剂 | |
CN105106139A (zh) | 一种治疗泌尿外科类疾病的药物他达拉非组合物颗粒剂 | |
CN103739514B (zh) | 一种金霉素硫酸氢盐的生产方法 | |
CN102793929B (zh) | 一种制备稳定非晶态药物制剂的方法 | |
CN115160258B (zh) | 一种氢溴酸沃替西汀γ晶型的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: XU DAN ZHOU PING Effective date: 20131125 Owner name: BEIJING KANGRUIDATONG MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LUO JUN Effective date: 20131125 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131125 Address after: 100039 Beijing city Haidian District West Hill Road No. 5 1104 Applicant after: Beijing Kangruidatong Medical Technology Co., Ltd. Address before: 100039 Beijing city Haidian District Xicui road five No. 3 1104 Applicant before: Luo Jun Applicant before: Xu Dan Applicant before: Zhou Ping |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150513 Termination date: 20190424 |